Search clinical trials for: Sofosbuvir (SOF) and Ledipasvir (LDV)

Total 146819 results

Ain Shams University
Cairo University

Completed

Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Hepatitis C, Chronic | Hematologic Malignancy

Egypt
Right to Care
Boston University; University of California, Los Angeles; Alliance for Public... and other collaborators

Completed

Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine

Hepatitis C Virus

Ukraine
University Health Network, Toronto

Terminated

Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

Hepatitis C Viral Infection

Canada
Yassin Abdelghaffar Charity Center for Liver Disease...

Unknown

Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir

Hepatitis C Genotype 4

Egypt
Icahn School of Medicine at Mount Sinai
Gilead Sciences

Completed

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

Hepatitis C | Cryoglobulinemia

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Duke University
Gilead Sciences

Completed

Hepatitis C Virus(HCV) Heart and Lung Study

Heart Failure | Pulmonary Disease, Chronic Obstructive | Hepatitis C, Chronic | Lung Diseases, Interstitial

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Hepatitis C | HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (SWIFT-C)

Hepatitis | HIV-1 Infection

United States
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

Chronic Genotype 4 HCV | Chronic Genotype 5 HCV

France
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

Hepatitis C Virus Infection

Taiwan
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

China, Korea, Republic of, Taiwan
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea

Hepatitis C Virus

Korea, Republic of
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

Hepatitis C

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Hepatitis C Infection With HIV Co-Infection

United Kingdom, Germany
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (ESRD)

Hepatitis C Virus Infection

United States, Taiwan, Belgium, Germany, Italy
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

Belgium, Austria, New Zealand, United Kingdom, Germany, Spain, Netherlands, France, Switzerland, Canada, Australia, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Hepatitis C Virus Infection

United States, Canada, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

HIV | Hepatitis C Virus

United States, New Zealand, Canada, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

HCV Infection

France
Janssen Sciences Ireland UC

Completed

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Hepatitis C, Chronic

Belgium
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Hepatitis C Virus Infection

Canada
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Estonia, Russian Federation
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Hepatitis C Virus Infection

France, Austria, Germany, Italy
Ain Shams University

Recruiting

PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders

HCV Infection | Beta Thalassemia Major

Egypt
Assiut University

Unknown

The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia

Hepatitis C

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
Mansoura University Children Hospital

Unknown

Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.

HCV | Gaucher Disease

Egypt
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

HCV Infection

New Zealand, United States, Puerto Rico
University Health Network, Toronto
Gilead Sciences

Completed

Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection

Hepatitis C, Chronic | Cirrhosis, Decompensated

Canada
Catherine Chappell
Gilead Sciences; University of Nebraska

Completed

Study of Hepatitis C Treatment During Pregnancy (HIP)

Hepatitis C | Pregnancy

United States
Instituto de Investigación Marqués de Valdecilla

Completed

Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) (JAILFREE-C)

Hepatitis C

Spain
Iran Hepatitis Network
Baqiyatallah Research Center for Gastroenterology and Liver Diseases

Unknown

Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients (HepCC-2)

Hepatitis C
University of California, San Francisco
National Institutes of Health Clinical Center (CC); Johns Hopkins University; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Completed

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (STOP-CO)

Hepatitis C | HIV | Cirrhosis

United States
Macfarlane Burnet Institute for Medical Research...
St Vincent's Hospital Melbourne

Unknown

The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach (TAP)

Hepatitis C | Drug Abuse, Intravenous

Australia
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

HCV Infection

United States, France, Australia, Puerto Rico, Spain
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs

Chronic Hepatitis C (Disorder)
Peter J. Ruane, M.D., Inc.

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Treatment of Hepatitis C

United States
Gilead Sciences

Completed

Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C

Japan
Third Affiliated Hospital, Sun Yat-Sen University

Completed

The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs

Chronic Hepatitis C
Sherief Abd-Elsalam

Unknown

Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C

Hepatitis C

Egypt

3

Subscribe